🚀 VC round data is live in beta, check it out!
Summit Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Summit Therapeutics and similar public comparables like Incyte, Innovent Biologics, Sichuan Biokin, Akeso and more.
Summit Therapeutics Overview
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Founded
2020
HQ
Employees
265
Website
Sectors
Financials (LTM)
EV
$19B
Summit Therapeutics Financials
Summit Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($971M).
In the same LTM period, Summit Therapeutics generated $2M in gross profit, ($971M) in EBITDA losses, and had net loss of ($998M).
Revenue (LTM)
Summit Therapeutics P&L
In the most recent fiscal year, Summit Therapeutics reported revenue of — and EBITDA of ($1B).
Summit Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($971M) | XXX | ($1B) | XXX | XXX | XXX |
| EBITDA Margin | (42344%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (45116%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($998M) | XXX | ($1B) | XXX | XXX | XXX |
| Net Margin | (43517%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Summit Therapeutics Stock Performance
Summit Therapeutics has current market cap of $20B, and enterprise value of $19B.
Market Cap Evolution
Summit Therapeutics' stock price is $25.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19B | $20B | 3.0% | XXX | XXX | XXX | $-1.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSummit Therapeutics Valuation Multiples
Summit Therapeutics trades at 8201.3x EV/Revenue multiple, and (19.4x) EV/EBITDA.
EV / Revenue (LTM)
Summit Therapeutics Financial Valuation Multiples
As of April 18, 2026, Summit Therapeutics has market cap of $20B and EV of $19B.
Equity research analysts estimate Summit Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Summit Therapeutics has a P/E ratio of (19.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20B | XXX | $20B | XXX | XXX | XXX |
| EV (current) | $19B | XXX | $19B | XXX | XXX | XXX |
| EV/Revenue | 8201.3x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (19.4x) | XXX | (17.4x) | XXX | XXX | XXX |
| EV/EBIT | (18.2x) | XXX | (17.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 11206.5x | XXX | — | XXX | XXX | XXX |
| P/E | (19.5x) | XXX | (18.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (58.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Summit Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Summit Therapeutics Margins & Growth Rates
Summit Therapeutics' revenue in the last 12 month grew by 1547%.
Summit Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $4.1M for the same period.
Summit Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1547% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (42344%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (30%) | XXX | (37%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21019% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23114% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Summit Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Summit Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Incyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Innovent Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sichuan Biokin | XXX | XXX | XXX | XXX | XXX | XXX |
| Akeso | XXX | XXX | XXX | XXX | XXX | XXX |
| Moderna | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Summit Therapeutics M&A Activity
Summit Therapeutics acquired XXX companies to date.
Last acquisition by Summit Therapeutics was on XXXXXXXX, XXXXX. Summit Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Summit Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSummit Therapeutics Investment Activity
Summit Therapeutics invested in XXX companies to date.
Summit Therapeutics made its latest investment on XXXXXXXX, XXXXX. Summit Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Summit Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Summit Therapeutics
| When was Summit Therapeutics founded? | Summit Therapeutics was founded in 2020. |
| Where is Summit Therapeutics headquartered? | Summit Therapeutics is headquartered in United States. |
| How many employees does Summit Therapeutics have? | As of today, Summit Therapeutics has over 265 employees. |
| Who is the CEO of Summit Therapeutics? | Summit Therapeutics' CEO is Mahkam Zanganeh. |
| Is Summit Therapeutics publicly listed? | Yes, Summit Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Summit Therapeutics? | Summit Therapeutics trades under SMMT ticker. |
| When did Summit Therapeutics go public? | Summit Therapeutics went public in 2015. |
| Who are competitors of Summit Therapeutics? | Summit Therapeutics main competitors are Incyte, Innovent Biologics, Sichuan Biokin, Akeso. |
| What is the current market cap of Summit Therapeutics? | Summit Therapeutics' current market cap is $20B. |
| What is the current revenue of Summit Therapeutics? | Summit Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Summit Therapeutics? | Summit Therapeutics revenue growth (NTM/LTM) is 1547%. |
| What is the current EV/Revenue multiple of Summit Therapeutics? | Current revenue multiple of Summit Therapeutics is 8201.3x. |
| Is Summit Therapeutics profitable? | No, Summit Therapeutics is not profitable. |
| What is the current EBITDA of Summit Therapeutics? | Summit Therapeutics has negative EBITDA and is not profitable. |
| What is Summit Therapeutics' EBITDA margin? | Summit Therapeutics' last 12 months EBITDA margin is (42344%). |
| What is the current EV/EBITDA multiple of Summit Therapeutics? | Current EBITDA multiple of Summit Therapeutics is (19.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.